Precigen (NASDAQ:PGEN) Price Target Raised to $9.00 at Citizens Jmp

Key Points

• Analyst update: Citizens Jmp raised its price target on Precigen from $8.00 to $9.00 and maintains a "market outperform" rating, while the MarketBeat consensus is a "Hold" with a $9.50 target, implying substantial upside from the current share price.
• PAPZIMEOS commercial progress: Management says the PAPZIMEOS launch is accelerating with broader U.S. payer coverage, a permanent CMS J‑code and EMA validation of the MAA, and expects Q1 revenue to exceed $18M backed by roughly $100.4M in cash and investments.
• Mixed near‑term performance: Q4 revenue of $4.57M missed estimates (~$8.29M) despite an EPS beat (‑$0.01 vs. ‑$0.10), the stock opened at $4.01 and has moved below its 200‑day moving average, with a market cap around $1.42B.

Precigen (NASDAQ:PGEN - Get Free Report) had its price objective upped by stock analysts at Citizens Jmp from $8.00 to $9.00 in a report issued on Thursday,Benzinga reports. The firm currently has a "market outperform" rating on the biotechnology company's stock. Citizens Jmp's price objective would indicate a potential upside of 124.72% from the company's current price.

Several other research analysts also recently commented on the stock. Zacks Research raised shares of Precigen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research note on Thursday, January 22nd. Finally, HC Wainwright increased their target price on shares of Precigen from $9.00 to $10.00 and gave the company a "buy" rating in a report on Thursday. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $9.50.

Precigen Stock Performance

Shares of NASDAQ PGEN opened at $4.01 on Thursday. The stock's 50-day moving average is $4.10 and its 200 day moving average is $3.98. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -2.92 and a beta of 1.10. Precigen has a 1-year low of $1.11 and a 1-year high of $5.47. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22.

Hedge Funds Weigh In On Precigen

Large investors have recently bought and sold shares of the stock. Patient Capital Management LLC grew its holdings in shares of Precigen by 62.6% in the third quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company's stock worth $87,056,000 after purchasing an additional 10,192,107 shares during the last quarter. Lansing Street Advisors bought a new stake in Precigen during the 3rd quarter valued at $1,800,000. Diametric Capital LP bought a new stake in Precigen during the 2nd quarter valued at $476,000. Boxer Capital Management LLC purchased a new stake in Precigen during the 3rd quarter valued at $2,796,000. Finally, Profund Advisors LLC bought a new stake in Precigen in the 3rd quarter worth $79,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Management said PAPZIMEOS launch is accelerating with broader U.S. payer coverage and expects Q1 revenue to exceed $18M, signaling strong early commercial demand. Precigen expects Q1 revenue to exceed $18M
• Positive Sentiment: PAPZIMEOS recorded $3.4M of net product revenue in Q4 (first partial commercial quarter); CMS assigned a permanent J‑code (J3404) effective April 1, and the EMA validated a Marketing Authorization Application — all steps that should simplify reimbursement and expand access. Company reports ~$100.4M in cash and investments to fund operations toward cash‑flow breakeven. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Reported EPS of ($0.01) beat consensus (-$0.10), indicating better‑than-expected per‑share performance despite being in a loss position. Precigen Q4 earnings details
• Neutral Sentiment: Management provided additional color on commercial execution and clinical programs during the earnings call and published call transcripts; listeners should review the call for details on sales cadence and launch execution. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Recent short‑interest reports in public feeds appear anomalous (showing zero shares), so short‑interest signals are unreliable at present; treat those data cautiously.
• Negative Sentiment: Q4 revenue of $4.57M missed analysts’ estimates (~$8.29M), a near-term financial disappointment that tempers enthusiasm around the launch ramp. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Technically, the stock has moved below its 200‑day moving average, which can trigger selling from trend‑based investors. Stock Passes Below 200-Day Moving Average

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.